Novavax Financial News

U.S. regulators have cleared a third updated COVID-19 vaccine for this fall, shots made by Novavax Inc. The Food and Drug Administration cleared updated shots made by Novavax on Friday

In this article

high efficacy" malaria vaccine co-developed by the Serum Institute of India (SII) and the University of Oxford was officially rolled out on Monday when Cote d'Ivoire in West Africa became the first country to begin administering R21/Matrix-M. The vaccine, which was granted World Health Organisation (WHO) approval last year, is said to have undergone a rigorous regulatory process and clinical assessment and was found to be highly effective and affordable. As a low-dose vaccine, it can be manufactured at speed and scale which is seen as critical to stemming the spread of the mosquito-borne disease. «Reducing the malaria burden is finally within sight. Today's start of the R21/Matrix-M vaccine roll-out marks a monumental milestone after years of incredible work with our partners at Oxford and Novavax,» said SII CEO Adar Poonawalla. «At Serum, we believe that it is every person's right to have access to affordable and essential disease prevention. That's why we have committed to producing 100 million doses of R21, which will protect millions of lives and alleviate the burden of this deadly disease for future generations,» he said.

Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started manufacturing that targets a variant that was dominant earlier this year, the company said.

U.S. stocks coasted to the close of another winning week with a quiet, mixed finish

Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in upfront payments as well as a further $700 million if all development, regulatory and launch milestones are met, according to a statement Friday. Novavax, which will receive tiered royalties on any vaccine sales, said Sanofi is also taking a minority equity stake of about 5% in the US company.

This initiative follows a summer surge in COVID-19 cases that sparked debates about masking in classrooms, leading to varied policies across different districts. Although there has been a slight decrease in COVID-19-related hospitalizations in recent months, there has been an uptick in the last few weeks, as indicated by the latest federal data. This announcement highlights the enduring impact of the coronavirus on American schools and society. It reflects the evolution from the challenges faced during the height of the pandemic, with limited testing availability, to the current efforts to ensure resources for testing are more widely accessible as schools navigate ways to stay open while prioritizing student safety. Novavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company said on Tuesday. The updated Novavax shot, which was authorized in the U.S. last month, targets a descendant of the XBB lineage of the coronavirus that was globally predominant earlier this year. The emergency use listing helps speed up the regulatory approvals to import and administer the vaccines by member states, according to the WHO. Novavax missed out on the COVID-19 vaccine windfall, which benefited mRNA rivals, due to manufacturing issues that delayed its filing for regulatory approval during the peak of the pandemic. Its original COVID shot received U.S. authorization in July 2022, long after Pfizer and Moderna vaccines were in use. Novavax's updated shot uses a more traditional protein-based technology than the mRNA-based vaccines by Pfizer and Moderna.

Check out the companies making headlines before the bell.

U.S. regulators have added another option for fall COVID-19 vaccination, updated shots made by Novavax

malaria vaccine jointly developed by University of Oxford and Serum Institute of India (SII), leveraging Novavax's adjuvant, has been recommended for use by the World Health Organization's Strategic Advisory Group of Experts and the Malaria Policy Advisory Group, paving the way for a global roll-out soon. The R21/Matrix-M malaria vaccine is an easily deployable vaccine that can be manufactured at mass scale at a modest cost, enabling as many as hundreds of millions of doses to be supplied to countries which are suffering a significant malaria burden, according to a news release posted on the Oxford University website.

Respiratory virus season is around the corner. With vaccines available for Covid-19, flu and, for some people, RSV, when should you get them? Doctors generally suggest getting your flu and Covid shots before the end of October, and say it’s OK to get both those shots at the same time. The most important thing, doctors say, is to get vaccinated.

Americans can now get an updated COVID-19 vaccine

Covid-19 vaccine to protect against the potentially serious outcomes of Covid-19 illness this fall and winter." Bloomberg reported, the statement further added, “Updated Covid-19 vaccines from Pfizer-BioNTech and Moderna will be available later this week." Cohen’s final green light means the shots can be administered across the US. The Food and Drug Administration has already approved them. Distribution of these boosters could be especially helpful for Pfizer, which has struggled amid a sharp decline in sales of its Covid vaccine and antivirals after a surge during the pandemic.

Pfizer/BioNTech and Moderna that target a recently circulating Omicron variant of the coronavirus, according to a report published by the news agency Reuters. A third shot, made by Novavax, is still under review by the US FDA. However, Novavax did not expect its shot to be authorized in the United States before a meeting of a Centers for Disease Control and Prevention (CDC) advisory panel on Tuesday.

(Reuters) — The U.S. drug regulator on Monday authorized updated COVID-19 vaccines from Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) that closely match the widely circulating Omicron variants, allowing the deployment of the shots to start as soon as this week.

Joe Biden tested negative for the viral disease, according to a report published by The Associated Press. White House press secretary Karine Jean-Pierre said the president would continue testing regularly and be monitored for symptoms. Jill Biden will remain at the couple's home in Rehoboth Beach, Delaware, for the time being.

Pfizer, Moderna and Novavax all plan to bring boosters to the market this fall. Pfizer expects to win Food and Drug Administration approval in August, with vaccinations starting in September. Novavax said it expects to get clearance and ship doses in September, and Moderna said it is waiting for approval.

President Biden announced on Friday his intention to seek further funding from Congress to support the development of a new COVID-19 vaccine.

Check out the companies making headlines in premarket trading.

(Reuters) -Novavax Inc said on Tuesday its updated protein-based COVID-19 vaccine generated an immune response against emerging forms of coronavirus such as the «Eris» subvariant in small studies in animals.

Joe Biden plans to urge all Americans to get a Covid-19 booster shot this autumn to counter a new wave of infections reported by the Centers for Disease Control and Prevention, said a White House official on Sunday as quoted by the news agency Reuters. Moderna on Thursday said that initial data showed its updated COVID-19 vaccine is effective against the "Eris" and "Fornax" subvariants in humans. Moderna and other Covid-19 vaccine makers Novavax, Pfizer, and German partner BioNTech SE have created versions of their shots aimed at the XBB.1.5 subvariant.